BioGend Therapeutics Co., Ltd. (TPEX: 6733)
Taiwan
· Delayed Price · Currency is TWD 37.00
+0.40 (1.09%)
Sep 11, 2024, 9:20 AM CST
BioGend Therapeutics Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Net Income | -120.92 | -156.33 | -184.46 | -138.49 | -145.59 | -162.9 | Upgrade
|
| Depreciation & Amortization | 54.02 | 55.02 | 53.18 | 28.19 | 19.19 | 18.11 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | - | 0.48 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | -26.7 | - | 39.95 | Upgrade
|
| Loss (Gain) on Equity Investments | -9.39 | -10.34 | - | 11.35 | 14.24 | 4.83 | Upgrade
|
| Other Operating Activities | -25.3 | -13.1 | -29.26 | -5.81 | -0.35 | -41.45 | Upgrade
|
| Change in Accounts Receivable | -21.48 | -15.42 | -6.22 | -4.72 | 0.03 | -0.31 | Upgrade
|
| Change in Inventory | -0.01 | -11.65 | 4.13 | 1.38 | -7.9 | -1.2 | Upgrade
|
| Change in Accounts Payable | 2.03 | 0.08 | 1.6 | -0.88 | 0.3 | 1.07 | Upgrade
|
| Change in Unearned Revenue | -2.5 | - | - | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -1.73 | 13.02 | 2.23 | -1.12 | 2.48 | -5.62 | Upgrade
|
| Operating Cash Flow | -125.27 | -138.72 | -168.78 | -136.8 | -117.13 | -147.53 | Upgrade
|
| Capital Expenditures | -8.45 | -26.04 | -18.18 | -0.67 | -0.2 | - | Upgrade
|
| Cash Acquisitions | - | - | - | 26.41 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | 0.32 | 0.32 | - | - | - | -31.38 | Upgrade
|
| Investment in Securities | -70.24 | -64 | 223.2 | -159.97 | -112.99 | -291.46 | Upgrade
|
| Other Investing Activities | -4.26 | 0.08 | -3.32 | -0.04 | -0.32 | - | Upgrade
|
| Investing Cash Flow | -82.63 | -89.64 | 201.7 | -134.27 | -113.51 | -322.84 | Upgrade
|
| Long-Term Debt Repaid | - | -3.58 | -4.81 | -1.78 | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -3.61 | -3.58 | -4.81 | -1.78 | - | - | Upgrade
|
| Issuance of Common Stock | - | 400 | - | 289.63 | 260 | 120 | Upgrade
|
| Other Financing Activities | - | - | - | - | 0.9 | - | Upgrade
|
| Financing Cash Flow | -3.61 | 396.42 | -4.81 | 287.85 | 260.9 | 120 | Upgrade
|
| Foreign Exchange Rate Adjustments | 2.94 | -1.19 | -0.79 | -0.49 | - | - | Upgrade
|
| Net Cash Flow | -208.57 | 166.87 | 27.32 | 16.28 | 30.27 | -350.37 | Upgrade
|
| Free Cash Flow | -133.72 | -164.76 | -186.96 | -137.47 | -117.33 | -147.53 | Upgrade
|
| Free Cash Flow Margin | -100.21% | -149.91% | -594.54% | -1483.13% | -8422.90% | -10098.15% | Upgrade
|
| Free Cash Flow Per Share | -1.09 | -1.37 | -1.81 | -1.36 | -1.34 | -1.82 | Upgrade
|
| Cash Interest Paid | 0.24 | 0.26 | 0.09 | 0.02 | 0.01 | - | Upgrade
|
| Cash Income Tax Paid | 0.33 | 0.2 | -0.18 | - | 0.12 | 0.18 | Upgrade
|
| Levered Free Cash Flow | -71.58 | -95.39 | -98.09 | -83.82 | -69.96 | -124.14 | Upgrade
|
| Unlevered Free Cash Flow | -71.42 | -95.23 | -98.04 | -83.81 | -69.96 | -124.14 | Upgrade
|
| Change in Net Working Capital | 21.51 | 14.19 | -3.97 | 8.63 | 5.44 | 6.43 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.